<DOC>
	<DOCNO>NCT01661855</DOCNO>
	<brief_summary>This study examine potential efficacy safety riluzole core associate symptom domains autism explore biological marker safety treatment response .</brief_summary>
	<brief_title>A Pilot Study Riluzole Versus Placebo Treatment Children Adolescents With ASD</brief_title>
	<detailed_description>There pharmacologic treatment available social function deficit individual Autism Spectrum Disorders ( ASD ) . The data pharmacologic treatment repetitive behavior disorder also become difficult interpret give last two large multisite trial selective serotonin reuptake inhibitor ( SSRIs ) autism report negative treatment repetitive behavior . Only associated symptom irritability 2 drug FDA indication whereas systematic data exist pharmacologic treatment anxiety ASD , response rate stimulants hyperactivity low see attention deficit hyperactivity disorder ( ADHD ) . In addition , biological marker treatment response identify population point . This study examine potential efficacy safety riluzole core associate symptom domains autism explore biological marker safety treatment response .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>1 . Male female outpatient 617 year age inclusive , mental age equivalent ≥ 18 month Screening visit . 2 . Meet Diagnostic Statistical Manual ( DSMIV ) criterion ASD . 3 . Have Clinician 's Global ImpressionSeverity ( CGIS ) score ≥ 4 ( moderately ill ) Screening . 4 . If already receive stable intervention must meet following criterion : 1 . If already receive stable concomitant medication affect behavior , must stable dose precede 1 month prior Screening ( exception fluoxetine , period 6 week need ) , electively initiate new modify ongoing medication study duration . 2 . If already receive stable nonpharmacological educational , behavioral , and/or dietary intervention , continuous participation precede 3 month prior Screening , electively initiate new modify ongoing intervention duration study . 5 . Have normal physical examination laboratory test result Screening . If abnormal , find ( ) must deem clinically insignificant Investigator . 6 . Ability complete assessment fluency English ( parent ; patient , verbal ) . 7 . Consent participate Province Ontario Neurodevelopmental ( POND ) study commitment complete many stage possible phenotyping measure ( Stages 1 , 2 3 ) , genomics component , interest image POND . 8 . Ability obtain write informed consent participant , developmentally appropriate . If participant capacity consent , ability obtain assent ( developmentally appropriate ) , well write inform consent parent ( ) /legal guardian . 1 . Pregnant female patient ; sexually active female patient inadequate birth control . 2 . Patients serious medical condition , base Investigator judgment , might interfere conduct study , confound interpretation study result , endanger wellbeing . Patients evidence history malignancy significant hematological , endocrine , cardiovascular ( include rhythm disorder ) , respiratory , renal , hepatic , gastrointestinal disease , include mild common pediatric disease area stable ( e.g . mild asthma , constipation , etc. ) . 3 . Patients unstable epilepsy ( i.e . seizure occur within last 6 month ) , patient epilepsy stable dos antiepileptic medication ( i.e . dose change within last 3 month ) . 4 . Patients hypersensitivity riluzole component formulation . 5 . Patients one following : HIV , Hepatitis B virus , Hepatitis C virus , hemophilia ( bleed problem , recent nose brain injury ) , abnormal blood pressure ( hypotension hypertension ) , drug abuse , immunity disorder , major depressive episode psychosis . 6 . Patients unable tolerate venipuncture procedure blood sample . 7 . Patients receive concomitant medication specifically target glutamate system ( e.g . memantine , dcycloserine ) , decrease elimination riluzole ( e.g . theophylline , quinolones ) , less 30 day prior screen visit . 8 . Patients actively enrol another intervention study . 9 . Patients unable swallow pill . 10 . Patients elevate liver enzyme ≥ 3 time normal amount study begin .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Autism Spectrum Disorders</keyword>
</DOC>